ChengDa Pharmaceuticals's earnings have been declining at an average annual rate of -51.1%, while the Pharmaceuticals industry saw earnings growing at 2.7% annually. Revenues have been growing at an average rate of 0.6% per year.
Key information
-51.06%
Earnings growth rate
-55.26%
EPS growth rate
Pharmaceuticals Industry Growth
10.90%
Revenue growth rate
0.60%
Return on equity
-0.17%
Net Margin
-0.77%
Next Earnings Update
26 Aug 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ChengDa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
XSEC:301201 Revenue, expenses and earnings (CNY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
458
-4
105
42
31 Dec 25
406
-12
112
40
30 Sep 25
374
-52
124
94
30 Jun 25
352
-40
113
95
31 Mar 25
309
-48
113
93
31 Dec 24
333
-28
98
94
30 Sep 24
398
70
91
41
30 Jun 24
412
87
94
37
31 Mar 24
413
90
87
32
31 Dec 23
414
91
87
27
30 Sep 23
366
76
78
21
30 Jun 23
361
71
81
20
31 Mar 23
405
100
85
19
01 Jan 23
411
106
89
19
30 Sep 22
432
122
90
20
30 Jun 22
438
115
83
19
31 Mar 22
436
106
76
18
01 Jan 22
416
100
68
17
30 Sep 21
396
126
103
31
31 Dec 20
373
121
55
19
31 Dec 19
294
54
52
12
31 Dec 18
203
7
46
9
Quality Earnings: 301201 is currently unprofitable.
Growing Profit Margin: 301201 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301201 is unprofitable, and losses have increased over the past 5 years at a rate of 51.1% per year.
Accelerating Growth: Unable to compare 301201's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 301201 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.6%).
Return on Equity
High ROE: 301201 has a negative Return on Equity (-0.17%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/07 11:39
End of Day Share Price
2026/07/07 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChengDa Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.